06159997 is referenced by 27 patents and cites 46 patents.

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy}benzyl)thiazolidi ne-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl}thiazolid ine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-d ione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]thiazol idine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

Title
Treatment of arteriosclerosis and xanthoma
Application Number
676090
Publication Number
6159997
Application Date
April 16, 1998
Publication Date
December 12, 2000
Inventor
Takashi Ito
Kobe
JP
Masashi Shiomi
Kobe
JP
Hiroyoshi Horikoshi
Tokyo
JP
Yoshio Tsujita
Tokyo
JP
Agent
Frishauf Holtz Goodman Langer & Chick P C
Assignee
Sankyo Company
JP
IPC
A61K 31/115
A61K 31/11
A61K 31/21
A61K 31/40
A61K 31/425
View Original Source